Federal Employee Program
Covered with requirementsWhat you need to qualify
- A1C of 6.5% or higher
- Lab results confirming eligibility
Qualification pathways
You can qualify through any one of these.
Initial approval for Type 2 Diabetes
All of:
- Diagnosis of type 2 diabetes mellitus
- No dual therapy with other GLP-1 receptor agonists
Plus any one of:
- HbA1c >= 6.5%
- History of fasting plasma glucose (FPG) >= 126 mg/dL
- History of 2-hour glucose >= 200 mg/dL during oral glucose tolerance test (OGTT)
- History of symptoms of hyperglycemia (polyuria, polydipsia, polyphagia) or hyperglycemic crisis AND random plasma glucose >= 200 mg/dL
Renewal for Type 2 Diabetes
All of:
- Diagnosis of type 2 diabetes mellitus
- Glycemic control has improved or stabilized while on therapy
- No dual therapy with other GLP-1 receptor agonists
Documentation to bring
- Documentation of type 2 diabetes mellitus diagnosis
- ONE of the following lab results: HbA1c >= 6.5%, fasting plasma glucose >= 126 mg/dL, 2-hour OGTT glucose >= 200 mg/dL, or random plasma glucose >= 200 mg/dL with symptoms of hyperglycemia or hyperglycemic crisis
- Attestation of no concurrent use of other GLP-1 receptor agonists
Quantity limits
- all strengths — 3 units per 84 days (84-day)
Approval and renewal
- Initial approval: 12 months
- Renewal: every 12 months
- To renew, the plan looks for improvement in A1C and Glycemic control has improved or stabilized while on therapy. No dual therapy with other GLP-1 receptor agonists. T2DM diagnosis is re-verified at continuation.
Not covered when
- Dual therapy with other GLP-1 receptor agonists
- Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Type 1 diabetes
Policy note: This policy covers Ozempic only for type 2 diabetes. Although Ozempic has FDA-approved indications for CV risk reduction in T2DM patients with established CVD and for CKD, this policy document (policy 5.30.086) addresses only the antidiabetic indication and does not establish separate PA criteria for those additional indications. The policy does not mention Wegovy or Zepbound for weight loss. The document covers only the antidiabetic GLP-1 class under this policy number. Per FEP policy history, liraglutide (Victoza) formulary exception requirement was removed in December 2024. Ozempic quantity limit is 3 units per 84 days.
Policy effective July 1, 2025 · verified June 5, 2026 · source: 5_30_086-Antidiabetic-GLP-1-GIP-Agonists.pdf